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Green tea, the fresh leaves of Camellia sinensis, is not only a health-promoting beverage
but also a traditional Chinese medicine used for prevention or treatment of cancer, such
as lung cancer. Theabrownin (TB) is the main fraction responsible for the medicinal
effects of green tea, but whether it possesses anti-cancer effect is unknown yet. This
study aimed to determine the in vitro and in vivo anti-lung cancer effect of TB and explore
the underlying molecular mechanism, by using A549 cell line and Lewis lung carcinoma-
bearing mice. In cellular experiment, MTT assay was performed to evaluate the inhibitory
effect and IC50 values of TB, and flow cytometry was conducted to analyze the cell cycle
progression affected by TB. In animal experiment, mice body mass, tumor incidence,
tumor size and tumor weight were measured, and histopathological analysis on tumor
was performed with Transferase dUTP nick-end labeling staining. Real time PCR and
western blot assays were adopted to detect the expression of C-MYC associated genes
and proteins for mechanism clarification. TB was found to inhibit A549 cell viability
in a dose- and time-dependent manner and block A549 cell cycle at G0/G1 phase.
Down-regulation of c-myc, cyclin A, cyclin D, cdk2, cdk4, proliferation of cell nuclear
antigen and up-regulation of p21, p27, and phosphate and tension homolog in both
gene and protein levels were observed with TB treatment. A c-myc-related mechanism
was thereby proposed, since c-myc could transcriptionally regulate all other genes in
its downstream region for G1/S transitions of cell cycle and proliferation of cancer cells.
This is the first report regarding the anti-NSCLC effect and the underlying mechanism of
TB on cell cycle progression and proliferation of A549 cells. The in vivo data verified the
in vitro result that TB could significantly inhibit the lung cancer growth in mice and induce
apoptosis on tumors in a dose-dependent manner. It provides a promising candidate of
natural products for lung cancer therapy and new development of anti-cancer agent.
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INTRODUCTION
Lung cancer has the highest incidence rate of cancer and
becomes the leading cause of cancer death (about 1.38 million
deaths annually) in the world (Siegel et al., 2015; Torre
et al., 2015). The estimated new cases and deaths from lung
cancer in the United States in 2016 were 224,390 and 158,080,
respectively (American Cancer Society, 2016). Non-small cell
lung cancer (NSCLC) comprises 80∼85% of lung cancer cases,
with an extremely poor 5-year survival rate of <15% and only
5∼10% survival rate for advanced NSCLC (Pore et al., 2013).
Despite considerable advances in lung cancer therapy, including
chemotherapy, radiotherapy, and immunotherapy, the overall
success in treating NSCLC remains unsatisfactory due to the
limited efficacy and/or serious side effects (Niyazi et al., 2011;
Iwamoto, 2013). Therefore, much attention has been focused on
anti-cancer agents derived from herbal medicines to change the
unsatisfactory situation, owing to their extensive efficacy and low
toxicity.
Green tea, the fresh leaves from the evergreen plant Camellia
sinensis (L.) O. Kuntze (Theaceae), is the most ancient health-
promoting beverage in the world. It has been officially described
as a medicine by the earliest national pharmacopeia ‘Xin Xiu
Ben Cao’ (Newly Revised Materia Medica, AD 659) in Tang
Dynasty of China, and was characterized with bitter and sweet
flavor as well as cold and non-toxic nature, which can function
to eliminate the heat, phlegm, and toxins from body. In the
traditional Chinese medicine (TCM) theory, heat, phlegm and
toxins are considered as causes of many chronic diseases, such
as cancer, resulting in the application of green tea by TCM for
the prevention/treatment of cancer (Yang et al., 2014). In recent
years, the anti-cancer activity of green tea, especially against lung
cancer, has been evidenced by various studies (Imai et al., 1997;
Yang et al., 2000; Cabrera et al., 2006; Suqanuma et al., 2011).
As the main pigments of green tea, theabrownin (TB), theaflavin
(TF) and thearubigin (TR) together determine the color, taste,
and the bioactivity of the tea liquor (Roberts et al., 1957). Of
these pigments, TB is a major fraction governing the medicinal
effects of green tea, such as cholesterol-lowering effect in relieving
fatigue and reducing blood lipid levels (Gong et al., 2010). In view
of the TB’s key role in green tea, it can be expected that TB has
a certain anti-lung cancer potential representative for the same
activity of green tea. However, whether it does is unknown yet.
Cell proliferation is dependent on the progression of the cell
cycle which is composed of the G1, S, G2 and M phases, and
the transition from the G1 to S phase is critical as it controls
the subsequent progress of the cell cycle (Luo et al., 2016). The
G1 to S phase transition is tightly regulated by the activation
of CDKs, which act consecutively in G1 to initiate the S phase
and in the G2 phase to initiate mitosis (Genovese et al., 2006;
Lim and Kaldis, 2013). Previous studies have reported that many
natural products could inhibit cell cycle progression (G0/G1
arrest) and proliferation of the NSCLC cells (A549 cell line),
indicating G0/G1 checkpoint in cell cycle as one of the most
conspicuous targets for anti-cancer agents. For determining the
anti-lung cancer effect of TB, this study employed A549 cells and
conducted cellular and molecular assays to evaluate TB’s effect on
cell cycle progression and proliferation of the NSCLC cells and
explore the underlying mechanism.
MATERIALS AND METHODS
Chemicals and Materials
Theabrownin powders (>90% of purity) and green tea crude
extract were provided by Theabio Co., Ltd (Hangzhou,
China; Batch number: 20151105001). Roswell Park Memorial
Institute (RPMI) 1640 medium, fetal bovine serum (FBS), and
0.25% trypsin were obtained from Gibco BRL (Grand Island,
NY, USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) and dimethyl sulfoxide (DMSO) were obtained
from Sigma (St. Louis, MO, USA). Cell cycle kit was obtained
from BD Biosciences (San Jose, CA, USA). All antibodies were
purchased from Cell Signaling Technology (CST, Danvers, MA,
USA). Trizol reagent and real time polymerase chain reaction
(real time PCR) kit were purchased from TaKaRa (Dalian, China).
Transferase dUTP nick-end labeling (TUNEL) staining kit was
purchased from Roche Applied Science (Indianapolis, IN, USA).
Cell Line and Animal
Human NSCLC A549 cell line and mouse Lewis lung carcinoma
(LLC) cell line were obtained from Shanghai Cell Bank of Chinese
Academy of Sciences (Shanghai, China) and cultured in RPMI-
1640 medium containing 10% FBS at 37◦C in a humidified 5%
CO2 incubator. The medium was changed daily and the cells
were used in their logarithmic growth phase. Male C57BL/6 mice
weighing 20∼22 g were purchased from Shanghai Laboratory
Animal Center of Chinese Academy of Sciences (Grade SPF II,
SCXK2012-0002) and housed under controlled pathogen-free
conditions with a 12 h light/dark cycle and allowed food and
water ad libitum. All animals were treated in strict accordance
with the China legislation on the use and care of laboratory
animals. The animal experiment was approved by the Medical
Norms and Ethics Committee of Zhejiang Chinese Medical
University.
MTT Assay
MTT assay was performed to evaluate the cell viability of A549
cells, as described in our previous report (Wu et al., 2016).
Cells were seeded on 96-well plates with density of 5 × 103
cells/well in 200 µl medium for 24 h and then treated with TB at
different concentrations (0, 5, 25, 50, 100, 150, 200, 300 µg/ml)
for 24, 48, and 72 h. Each 20 µl MTT solution (5.0 mg/ml) was
added to each well and incubated at 37◦C for 4 h. Then 150 µl
DMSO was added in each well to dissolve the MTT formazan
crystals and the optical density value (OD value) was measured at
490 nm with a microplate reader (Bio-Rad, Berkeley, CA, USA).
Inhibitory rate (%)= [1− (TB− treated OD/untreated OD)]
×100% . The 50% inhibitory concentrations (IC50) for 24, 48,
and 72 h were calculated by regression analysis, respectively.
Cell Cycle Analysis
Cell cycle analysis was performed with flow cytometry, as
described in our previous report (Wu et al., 2016). Briefly, A549
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cells were seeded on 6-well plates with density of 3 × 105
cells/well for 24 h, followed by TB treatment for 24, 48, and
72 h. The cells were harvested and washed with PBS thrice and
suspended in cold phosphate-buffered saline. Cells were then
stained with PI/RNase staining solution (20 µg/ml PI, 10 µg/ml
DNase free RNase) at 37◦C in dark for 30 min. The cell cycle
was analyzed in three replicates using flow cytometry (Beckman
Coulter, USA).
Real Time PCR Analysis
After TB treatment, gene expression in A549 cells was detected
by real time PCR assay on an ABI QuantStudioTM 7 Flex
Real-Time PCR System (Applied Biosystems, Foster City,
CA, USA), according to our previous report (Wu et al.,
2016). The total RNA of the cells in each group was extracted
using Trizol reagent and synthesized to cDNA via reverse
transcription. PCR reaction system had a 20.0 µl volume:
10.0 µl SYBR R© Premix Ex Taq II (Tli RnaseH Plus), 0.8 µl
PCR Forward Primer, 0.8 µl PCR Reverse Primer, 2.0 µl
template cDNA, 0.4 µl ROX Reference Dye, and 6.0 µl ddH2O.
The qPCR reaction condition was set to 95◦C for 30 s initial
denaturation, 40 cycles of 95◦C for 5 s denaturation, 60◦C
for 34 s annealing, and 72◦C for 40 s extension. At the end
of each reaction, a melting curve analysis was performed.
β-actin was used as the reference gene and 2−11CT method
was applied to analyze the relative expression of gene C-
MYC (forward: GCCACGTCTCCACACATCAG; backward:
TGGTGCATTTTCGGTTGTTG), CYCLIN D (forward: CAA
TGACCCCGCACGATTTC; backward: CATGGAGGGCGGA
TTGGAA), CYCLIN A (forward: GGATGGTAGTTTTGAGTCA
CCAC; backward: CACGAGGATAGCTCTCATACTGT), P21
(forward: GGCAGACCAGCATGACAGATT; backward: GC
GGATTAGGGCTTCCTCT), P27 (forward: TGGAGAAGCACT
GCAGAGA; backward: GCGTGTCCTCAGAGTTAGCC), CDK2
(forward: GCTAGCAGACTTTGGACTAGCCA; backward: AG
CTCGGTACCACAGGGTCA), CDK4 (forward: AAATCTTT
GACCTGATTGGG; backward: CCTTATGTAGATAAGAGTG
CTG), PCNA (forward: GTAGTAAAGATGCCTTCTGGTG;




Following TB treatment, A549 cells were harvested and washed
thrice with cold PBS. As previously described (Wu et al., 2016),
the cell pellets were resuspended in cell lysis buffer (50 mM
Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton,
0.1% SDS, 5 µg/ml leupeptin, and 1 mM PMSF) for 30 min
on ice repeated freezing and thawing for three times. After cold
centrifugation at 14,000 r/min for 20 min, the supernatant was
collected and stored at −80◦C. The lysed protein was quantified
using a BCA protein assay kit. Appropriately 20 µg of lysed
protein was boiled in 4x sample buffer and separated by a
denaturing SDS-PAGE (8∼12%). The gels were transferred onto
polyvinylidene fluoride membranes (Millipore, Billerica, MA,
USA) and blocked with 5% non-fat milk for 2 h, followed by
overnight incubation at 4◦C with the primary antibodies: c-Myc,
Cyclin A, Cyclin D, P21, P27, Cdk2, Cdk4, proliferation of
cell nuclear antigen (PCNA), phosphate and tension homolog
(PTEN), and β-tubulin. Following incubation with peroxidase-
conjugated goat anti-rabbit IgG at room temperature for 2 h,
proteins were visualized using enhanced chemiluminescence
kit (Amersham Pharmacia Biotech, Little Chalfont, UK) and
detected using a chemiluminescence analyzer.
Lewis Lung Carcinoma (LLC)-Bearing
Mouse Model Establishment and TB
Treatment
To establish the lung cancer model of mouse, LLC cells (1.0× 107
cells in 0.1 ml of PBS) were injected subcutaneously into 40 mice.
The mice were randomly divided into four groups of 10 mice
each: model group, low-dose TB group, middle-dose TB group,
and high-dose TB group. After the injection, mice in the low-
dose TB, middle-dose TB, and high-dose TB groups were daily
treated with 0.1 g/kg, 0.2 g/kg, and 0.4 g/kg mice body weight by
oral administration for 21 days, respectively.
Evaluation of In vivo Anti-tumor Effect of
TB
Mouse body weight of each mouse in each group was measured
per 3 days, and the tumor growth was observed for recording
tumor incidence. On day 21, all mice were sacrificed and each
tumor was sampled for size and weight measurement. The tumor










In situ Apoptosis Assay
As previously described, the tumor tissue in each mouse was
dissected, fixed in 10% formaldehyde for 24 h, and embedded
in paraffin wax. Sections (2∼3 µm) were stained by terminal
deoxynucleotidyl TUNEL using the in situ cell death detection
kit (Roche) according to the manufacturer’s instructions to detect
the apoptotic cells (Zhang et al., 2017). Apoptotic cells were
manifested by green staining in the nuclei under microscopy and
five microscopic fields (×400) of each section were randomly
examined, and the positive cells were counted by a single-blinded
observer in a coded randomized order.
Statistical Analysis
Data were expressed as mean ± SD and subjected to one-
way ANOVA, followed by Fisher’s least significant difference
(LSD) comparison. All analyses were performed using an updated
version of DPS software (Tang and Feng, 2007).
RESULTS
TB Inhibits Cell Viability of A549 Cells
As shown by MTT assay in Figure 1, TB treatment caused an
obvious inhibition of A549 cell viability at various concentrations
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FIGURE 1 | Effect of Theabrownin (TB) and green tea extract on cell viability of A549 cells determined by MTT assay. Values were presented as
mean ± SD (n = 5).
(5∼300 µg/ml) for 24, 48, and 72 h. The inhibitory effect
was increased with increasing concentrations at each time
point and was also increased with increasing time period
at each concentration point, indicating a dose- and time-
dependent manner of TB. The IC50 values were 239.89 ± 13.78,
145.80 ± 33.67, and 63.93 ± 35.44 µg/ml for 24, 48, and 72 h
treatment, respectively. The green tea extract could also induce
cell viability inhibition at the same concentration range for 24, 48,
and 72 h, but the effect was weaker than that of TB. The 200µg/ml
was selected as a high effective dose of TB for the following assays.
TB Induces Cell Cycle Arrest at G0/G1
Phase in A549 Cells
As shown by flow cytometry in Figure 2, TB-treated A549
cells was accumulated in the G0/G1 phase of the cell cycle,
with a significant increase of cell number in the G0/G1 phase
as compared to controls (all P < 0.05). Correspondingly, the
number of cells in the S phase and G2/M phase were significantly
decreased except for that in the G2/M phase at 24 h. These trends
indicated that TB could induce cell cycle arrest of A549 cells in
G0/G1 phase.
TB Modulates Cell Cycle Associated
mRNA and Protein Expression
As shown by real time PCR in Figure 3, the mRNA expression
of cell cycle associated genes were significantly modulated by
TB (200 µg/ml) after 24 to 72 h treatment. Of these genes, C-
MYC, CYCLIN A, CYCLIN D, CDK2, CDK4, and PCNA were
down-regulated while P21, P27, and PTEN were up-regulated,
as compared to the control. Mostly, the modulation effect of
TB on those genes displayed a time-dependent manner. In
accordance with this result, western blot analysis also showed
a similar trend of protein expressions encoded by those genes
(Figure 4).
In vivo Anti-tumor Effect of TB
As shown in Figure 5, the mice body weight in LLC
model group was gradually changed after LLC injection and
even decreased after day 9. In TB-treated groups, the mice
body weight kept increase with a dose dependent manner
of TB treatment, suggesting a recovery of physiological state
induced by TB. In each group, LLC tumor growth could
be visually seen at day 9 and the tumor incidence among
all groups were differed, in which the model group had
the highest incidence but the TB-treated groups had lesser
ones (Table 1). On day 21, the tumor volume in the model
group was significantly bigger than that in the TB-treated
groups, showing that TB could significantly inhibit the LLC
growth in a dose-dependent manner (Figure 6). TUNEL
assay also showed a consistent result that TB could induce
remarkable apoptosis in LLC tumors in a dose-dependent
manner (Figure 7).
Frontiers in Pharmacology | www.frontiersin.org 4 February 2017 | Volume 8 | Article 75
fphar-08-00075 February 23, 2017 Time: 13:44 # 5
Zhou et al. Theabrownin Inhibits Lung Cancer Growth
FIGURE 2 | Effect of TB on cell cycle of A549 cells determined by flow cytometry. Values were presented as mean ± SD (n = 3). ∗P < 0.05 and ∗∗P < 0.01
for comparison between control group and TB group.
FIGURE 3 | Relative mRNA expression of target genes in A549 cells with TB treatment at 200 µg/ml for 24, 48, and 72 h. Values are presented as
mean ± SD of three replicates. Different symbols (a, ab, b, c, bc, d) indicate significant difference between groups [Fisher’s least significant difference (LSD),
P < 0.05], and the values decrease with the order from a to d.
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FIGURE 4 | Protein expression of target genes in A549 cells with TB
treatment at 200 µg/ml for 24, 48, and 72 h.
DISCUSSION
There has been a growing interest in ethnopharmacological use
of TCMs as a new strategy for anti-cancer treatment, owing to
their advantages of high bioactivities and low toxicity. As the
most common beverage and also a TCM, green tea was found
with anti-cancer activity against e.g., lung cancer. A 10-year
epidemiological survey on 8,552 individuals has concluded that
over 10 cups of green tea per day could delay the cancer onset
among the general population (Nakachi et al., 2000). The need of
drinking over 10 cups means that the anti-cancer effect of green
tea may rely on the accumulation of some kind of low-content
component. Thus, to find out what component dominates the
anti-cancer effect of green tea is of practical necessity, so that
it can be concentrated and developed into an efficient agent for
cancer treatment. In the present study, we focused on the anti-
cancer effect and the underlying mechanism of TB on NSCLC
cells, in view of the fact that green tea has anti-NSCLC effect and
TB acts as its main component (Roberts et al., 1957; Khan et al.,
2009; Yang et al., 2009).
Our results demonstrated that TB inhibited A549 cell viability
in a dose- and time-dependent manner and blocked A549 cell
cycle at G0/G1 phase (Figure 1). The real time PCR and western
blot analyses have clarified the associated mechanism that TB
induced cell cycle arrest through down-regulation of c-myc,
cyclin A, cyclin D, cdk2, cdk4, PCNA and up-regulation of p21,
p27, and PTEN (Figure 2). The c-myc is a transcriptional factor
and a well known oncogene expressed in G1 phase of cell cycle,
FIGURE 5 | Mice body weight of all groups (n = 10).
TABLE 1 | Tumor incidence (%) of Lewis lung carcinoma (LLC)-bearing mouse model with TB treatment (n = 10).
Day1 Day3 Day5 Day7 Day9 Day11 Day13 Day15 Day17 Day19 Day21
Normal 0 0 0 0 0 0 0 0 0 0 0
Model 0 0 0 0 90 100 100 100 100 100 100
Low-dose TB 0 0 0 0 40 70 100 100 100 100 100
Middle-dose TB 0 0 0 0 10 50 90 100 100 100 100
High-dose TB 0 0 0 0 10 40 100 100 100 100 100
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FIGURE 6 | Tumor volume of mice in all groups (n = 10). Different
symbols (a, ab, bc, c) indicate significant difference between groups (Fisher’s
LSD, P < 0.05), and the values decrease with the order from a to c.
Bar = 1 cm.
which induces DNA synthesis by direct control of the initiation
of DNA replication or by transcriptional regulation of the genes
involved in DNA replication (Dominguez-Sola et al., 2007).
Dysfunctional overexpression of c-myc is commonly observed
in a wide range (roughly 70%) of human tumors and intensely
associated with the cell proliferation in numerous malignancies,
whereas inhibition of c-myc results in cell cycle arrest and
decreased cell proliferation (Nesbit et al., 1999; Delmore et al.,
2011). The downstream genes targeted by c-myc for cell cycle
regulation are cyclin A, cyclin D, PCNA, p21, p27, PTEN, etc.
(Hoang et al., 1994; Grandori et al., 2000; Guo et al., 2000; Zhang
et al., 2010; Ott et al., 2013; Shao et al., 2014).
The cyclin A is a member of cyclin family, the transcription
of which is tightly regulated and synchronized with cell cycle
progression (Soucek et al., 1997). It promotes both cell cycle G1/S
and G2/M transitions by binding and activating cdk2, a member
of the cyclin-dependent kinase family of serine/threonine protein
kinases (Mendoza et al., 2003). Complex of cyclin A and cdk2
is required to progress through the S phase and plays important
role in G1 cell cycle arrest of cancer cells (Morgan, 1995; Kokontis
et al., 2014). As another downstream gene of c-myc and also
cyclin family member, cyclin D is the major G1 phase cyclin
and is overexpressed in most cancer cells (Christopher et al.,
2004). Complex of cyclin D and cdk4 is necessary to regulate
G1/S transition in the cell cycle progression (Sherr, 1996). PCNA
is also a c-myc-targeted gene that produces a 36 kD nuclear
protein in late G1 and S phases for cell proliferation, DNA
repair and cell cycle control (Strzalka and Ziemienowicz, 2010).
FIGURE 7 | Transferase dUTP nick-end labeling (TUNEL) and DAPI
staining on mice tumors and the TUNEL-positive cell number
comparison among all groups. Different symbols (a, b, c, d) indicate
significant difference between groups (Fisher’s LSD, P < 0.05), and the values
decrease with the order from a to d.
FIGURE 8 | c-myc-related mechanism of TB on A549 cells.
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Down-regulation of PCNA could induce cell cycle arrest and
cell proliferation inhibition of cancer cells (A549; Chairuangkitti
et al., 2013). The cdk inhibitors, p21 and p27, are known
downstream targets of c-myc and capable of binding to and
inhibit the active cyclin/cdk complexes as well as PCNA in the
nucleus (Grandori et al., 2000). Through their binding to cdk2
and cdk4, p21 and p27 have been reported to induce blockade
of G1/S transitions of cell cycle and then premature senescence in
cancer cells (Kuilman et al., 2010). Likewise, by binding to PCNA,
p21 blocks the stimulation ability of PCNA to DNA polymerases
and leads to DNA replication inhibition and cell cycle arrest
(Moldovan et al., 2007; Abbas and Dutta, 2009). PTEN is a crucial
tumor suppressor in many cancer types, the gene of which is
negatively regulated by c-myc (Zhang et al., 2010). It decreases
cell proliferation through cell cycle arrest in G0/G1 phase and is
frequently mutated or lost in many kinds of cancers (Gottschalk
et al., 2001). The decrease of PTEN expression is correlated with
poor prognosis of cancers, and vice versa (Jiang and Liu, 2008).
The above are all c-myc targets associated with G1/S transitions
of cell cycle and proliferation of cancer cells. In this study, with
TB treatment, they showed a consistent expression trend with
each other, toward G1 cell cycle arrest and proliferation inhibition
of A549 cells. Therefore, a mechanism can be proposed that
TB directly inhibited the overexpression of C-MYC and then
transcriptionally regulated the downstream genes as we listed
above. It has been found that MAPK and NF-κB are the upstream
signaling molecules of C-MYC, activation of which positively
correlates with c-myc-mediated cell proliferation and cell cycle
progression in lung cancer (Tang et al., 2013; Lim et al., 2016).
Other publications reported that tea and its components could
inhibit human cell growth and migration by inhibiting MAPK or
NF-κB signaling (Karki et al., 2011; Liu et al., 2016; Zhou et al.,
2016), suggesting the potential importance of those signaling
molecules in the role of TB. Therefore, more studies in future are
needed to explore MAPK and NF-κB signaling pathways in the
c-myc-related mechanism of TB.
The induction of cell cycle arrest is an important mechanism
involved in anticancer agents (Swanton, 2004). In particular,
cell cycle arrest in the G1 phase is of potentially great clinical
value, because the G1 phase is the most sensitive time point
for cancer therapy. A cell cycle restriction point occurs in
the mid-G1 phase, and after this point, cancer cells become
independent of growth factors and become committed to cell
division (Kastan and Bartek, 2004). For example, cancer cells
appear to be maximally sensitive to cisplatin in the G1 phase
and minimally sensitive in peak DNA-synthesis phase, then
with a twofold decrease in the S phase (Shah and Schwartz,
2001). Studies have reported that the down-regulation of c-myc
expression can also enhance sensitivity to chemotherapeutic
drugs as cisplatin (Xie et al., 2006, 2009). Taken together,
TB may not only suppress cancers by itself but also facilitate
the effect of chemotherapeutics by increasing cancer cell
sensitivity, owing to its c-myc-related mechanism of G1 cell cycle
arrest.
In the present study, TB induced G1 cell cycle arrest
and proliferation inhibition of A549 cells by regulation of
c-myc and its downstream genes, indicating an anti-NSCLC
effect through c-myc-related mechanism (Figure 8). The
results provide evidences that TB dominates and represents
the anti-cancer effect of green tea, and that it may facilitate
chemotherapy by enhancing cell sensitivity of cancers. We
have also evaluated the effect of TB on human embryonic
lung fibroblast (HFL1 cell line) by MTT assay and found
its cytotoxic dose was upon 1000 µg/ml (data not shown).
Within the mentioned dose range between 5 to 300 µg/ml,
no toxicity was seen in MTT assay. Therefore, TB induces
specific anti-lung cancer effect in this study. Therefore, TB
deserves further study in combination with chemotherapeutics
for the treatment of NSCLC in vivo, contributing to
the development of a new anti-cancer agent from green
tea.
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